Teva wins FDA approval for DEGEVMA biosimilar across all Xgeva indications
FDA approves Teva’s DEGEVMA as an Xgeva biosimilar across oncology bone-disease indications, expanding its U.S. denosumab portfolio.
Pharma & Biotech
Pharma & Biotech
Bristol Myers Squibb sues Amgen over Opdivo biosimilar as $10bn franchise nears patent cliff
Bristol Myers Squibb and Ono Pharmaceutical are suing Amgen over seven patents tied to its proposed Opdivo biosimilar ABP 206, opening an important legal battle around a cancer drug that generated more than $10 billion in 2025.
Pharma & Biotech
Amgen removes an Imdelltra treatment burden just as its DLL3 therapy approaches a much larger first-line opportunity
The FDA has reduced monitoring requirements around the first two Imdelltra doses, lowering an important logistical burden days after Amgen reported positive Phase 3 survival data in first-line extensive-stage small cell lung cancer.
Pharma & Biotech
GSK’s Ris-Rez cuts death risk 54% in relapsed small cell lung cancer as ADC pipeline gains weight
GSK’s licensed B7-H3 antibody-drug conjugate Ris-Rez delivered median survival of 18.5 months versus 10.3 months with topotecan in a Chinese Phase 3 study, strengthening the company’s case for global development.
Pharma & Biotech
Only about 40% of extensive-stage SCLC patients reach second-line therapy. Amgen and AstraZeneca are moving Imdelltra earlier
Amgen’s Phase 3 DeLLphi-305 trial met its primary overall survival endpoint with Imdelltra plus Imfinzi as first-line maintenance in extensive-stage small cell lung cancer.
Pharma & Biotech
Repatha cut deaths by 20% in high-risk patients who had never had a heart attack or stroke
A prespecified VESALIUS-CV analysis found a 20% reduction in mortality with Amgen’s Repatha among more than 12,000 high-risk adults without a previous heart attack or stroke, strengthening the case for intensive LDL lowering before the first major cardiovascular event.
Pharma & Biotech
TEZSPIRE clears every major Phase 3 hurdle in EoE. Could blocking TSLP reshape another disease?
Amgen and AstraZeneca say TEZSPIRE achieved both co-primary and all key secondary endpoints in the Phase 3 CROSSING study, potentially extending the TSLP-blocking biologic into eosinophilic esophagitis.
Features & Analysis
Dr. Raymond Douglas weighs Amgen’s Tepezza as Viridian’s Lumvoa widens TED choices
Amgen’s Tepezza is facing a broader thyroid eye disease treatment landscape after Viridian Therapeutics’ Lumvoa became another approved option, shifting attention toward how physicians may weigh evidence, safety, treatment burden and patient fit. Dr. Raymond Douglas, MD, PhD, who served as principal investigator in the international Tepezza trials that supported its United States Food and
Pharma & Biotech
Jubereq launch: Accord BioPharma challenges Xgeva in cancer-related bone complications
Accord BioPharma launches Osvyrti and Jubereq as interchangeable denosumab biosimilars, testing price, payer access and provider adoption.
Pharma & Biotech
FDA approves Lumvoa for thyroid eye disease as Viridian enters commercial biotech
See how Lumvoa’s FDA approval could reshape thyroid eye disease treatment, challenge Tepezza and test Viridian’s launch strategy.